Status:

COMPLETED

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Lead Sponsor:

Command Hospital, India

Conditions:

Type 1 Diabetes

Eligibility:

All Genders

12-30 years

Phase:

PHASE4

Brief Summary

To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.

Detailed Description

Inclusion criteria T1DM \<3 months GAD Antibody+ Stimulated C peptide\<0.5ng/ml Ketosis at onset Age \< 30 yr Exclusion criteria Age \> 30 yr Pancreatic disease significant systemic complication

Eligibility Criteria

Inclusion

  • T1DM \<3 months
  • GAD Antibody+ or Stimulated C peptide\<0.5 ng/ml
  • Ketosis at onset
  • Age \< 30 yr

Exclusion

  • Age \> 30 yr
  • Pancreas disease
  • Significant systemic disease

Key Trial Info

Start Date :

November 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2011

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT01235819

Start Date

November 1 2010

End Date

September 1 2011

Last Update

July 27 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Command Hospital

Lucknow, Uttar Pradesh, India, 226002

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus | DecenTrialz